Live Breaking News & Updates on Fruquintinib

Stay updated with breaking news from Fruquintinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Toxicity Considerations and Treatment Decisions in CRC

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib. ....

Adverse Event Management , Colorectal Cancer , Optimizing Treatment Approaches , Treatment Decisions , Colorectal Cancer Treatment , Mcrc Treatment , Safety Profile , Fresco 2 ,

Monitoring and AE Management Strategies with Fruquintinib in CRC

Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib. ....

Adverse Event Management , Colorectal Cancer , Optimizing Treatment Approaches , Colorectal Cancer Treatment , Mcrc Treatment , Adverse Effects , Adverse Effect Management , Mae Management , Monitoring Strategies ,

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer. ....

Adverse Event Management , Colorectal Cancer , Optimizing Treatment Approaches , Refractory Metastatic , Colorectal Cancer Treatment , Mcrc Treatment , Fresco 2 , Refractory Colorectal Cancer , Refractory Crc , Tas 102 , Safety Profile , Sunlight Trial ,

Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma

Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer. ....

Junshi Biosciences , Astellas Pharma , Rui Hua Xu , Merck Serono , Sun Yat Sen University Cancer Center , Bristol Myers Squibb , Phase 3 Frutiga Study Nct03223376 , February 2024 Asco Plenary Series , Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma ,

HUTCHMED Announces Marketing Approval For ELUNATE By Pharmacy And Poisons Board Of Hong Kong

HUTCHMED China (?HCM) announced marketing approval of ELUNATE, or fruquintinib by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer. ....

Hong Kong , Noord Holland , Philips Electronics , China Evergrande Group , Drug Administration , Neptune Resources ,